Get the Stockscreener App
46.87
1.21%
+0.56
Keros Therapeutics Inc stock is currently priced at $46.87, with a 24-hour trading volume of 389.26K.
It has seen a +1.21% increased in the last 24 hours and a -16.88% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $46.60 pivot point. If it approaches the $47.31 resistance level, significant changes may occur.
Previous Close:
$46.31
Open:
$46.68
24h Volume:
389.26K
Market Cap:
$1.69B
Revenue:
-
Net Income/Loss:
$-152.99M
P/E Ratio:
-10.32
EPS:
-4.54
Net Cash Flow:
$-126.97M
1W Performance:
-3.32%
1M Performance:
-16.88%
6M Performance:
+54.48%
1Y Performance:
-2.07%
1D Range:
$45.34
$47.14
52W Range:
$27.02
$73.00
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
99 Hayden Avenue, Suite 120 Building E, Lexington, MA
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Defense World
Ratio Analysis: Unpacking Keros Therapeutics Inc (KROS)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
The Dwinnex
Keros Therapeutics adds biotech veteran to board - Investing.com India
Investing.com India
Keros Therapeutics adds biotech veteran to board - Investing.com ZA - Investing.com South Africa
Investing.com South Africa
Keros Therapeutics adds biotech veteran to board By Investing.com - Investing.com Australia
Investing.com Australia
Keros Therapeutics adds biotech veteran to board By Investing.com - Investing.com
Investing.com
Keros Therapeutics Inc Stock (KROS) Financials Data
Keros Therapeutics Inc (KROS) Net Income 2024
KROS net income (TTM) was -$152.99 million for the quarter ending December 31, 2023, a -46.15% decrease year-over-year.
Keros Therapeutics Inc (KROS) Cash Flow 2024
KROS recorded a free cash flow (TTM) of -$126.97 million for the quarter ending December 31, 2023, a -78.07% decrease year-over-year.
Keros Therapeutics Inc (KROS) Earnings per Share 2024
KROS earnings per share (TTM) was -$5.20 for the quarter ending December 31, 2023, a -25.30% decline year-over-year.
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
0.79%
3.50%
Cap:
|
Volume (24h):